Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) An antiviral preparation characterized by comprising as an active ingredient, at least a phorbol derivative of formula 1:



1

wherein R_1 is a group of $-(CH_2)_aX(CH_2)_bCH_3$ wherein X is O or S, a is a number of 1 to 3, and b is a number of 0 to 5, a group of $-(CH_2)_cX(CH_2)_dYCH_3$ wherein X and Y are O or S, c is a number of 1 to 3, and d is a number of 1 to 5, ~~a group of $-CO(CH_2)_eCH_3$ wherein e is a number of 0 to 12,~~ or a group of $-(CH_2)_fCH_3$ wherein f is a number of 0 to 5,

R_2 is a group of $-CO(CH_2)_nCH_3$ wherein n is a number of 3 to 12, and

R_3, R_4 and R_5 are independently of one another, hydrogen atom, or an aliphatic or aromatic carboxylic acid residue, and

having a specific safety index S.I. = CC_{50}/EC_{50} of 10 or more wherein EC_{50} means a concentration at which HIV-1 induced cytopathogenic effect (CPE) in MT-4 cell is inhibited by 50%, and CC_{50} means a concentration at which survival of MT-4 cell in a cell proliferation test is reduced by 50%.

2. (Original) The antiviral preparation according to claim 1, wherein R_1 in formula 1 is a group of $-(CH_2)_aX(CH_2)_bCH_3$ wherein X is O or S, a is a number of 1 to 3, and b is a number of 0 to 5.

3. (Original) The antiviral preparation according to claim 1, wherein R_1 in formula 1 is a group of $-(CH_2)_cX(CH_2)_dYCH_3$ wherein X and Y are O or S, c is a number of 1 to 3, and d is a number of 1 to 5.

4. (Canceled)

5. (Original) The antiviral preparation according to claim 1, wherein R_1 in formula 1 is a group of $-(CH_2)_fCH_3$ wherein f is a number of 0 to 5.

6. (Canceled)

7. (Original) An anti-HIV virus preparation comprising at least one of phorbol derivatives of formula 1 according to claim 1, and at least one of other agents having anti-HIV effect.

8. (Original) The anti-HIV virus preparation according to claim 7, characterized in that the other agent having anti-HIV effect is a reverse transcriptase inhibitor.

9. (Original) The anti-HIV virus preparation according to claim 7, characterized in that the other agent having anti-HIV effect is an agent that inhibits an integration of DNA mediated by an integrase.

10. (Original) The anti-HIV virus preparation according to claim 7, characterized in that the other agent having anti-HIV effect is an agent that suppresses a transcription of provirus.

11. (Original) The anti-HIV virus preparation according to claim 7, characterized in that the other agent having anti-HIV effect is an agent that inhibits a synthesis of core protein mediated by a protease.

12. (Original) The anti-HIV virus preparation according to claim 7, characterized in that the other agent having anti-HIV effect is an agent that suppresses an assembly and packaging of core proteins.

13. (Original) The anti-HIV virus preparation according to claim 7, characterized in that the other agent having anti-HIV effect is an agent that suppresses an aggregation of core proteins and extra-shell proteins.

14. (Original) The anti-HIV virus preparation according to claim 7, characterized in that the other agent having anti-HIV effect is an agent that suppresses a maturity of infectious virus particles released and escaped from cell membrane.